<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Sangeeta Goswami(The University of Texas MD Anderson Cancer Center), Yulong Chen(The University of Texas MD Anderson Cancer Center), Swetha Anandhan(The University of Texas MD Anderson Cancer Center), Péter M. Szabó(Bristol-Myers Squibb (Sweden)), Sreyashi Basu(The University of Texas MD Anderson Cancer Center), Jorge Blando(The University of Texas MD Anderson Cancer Center), Wenbin Liu(The University of Texas MD Anderson Cancer Center), Jan Zhang(The University of Texas MD Anderson Cancer Center), Seanu Meena Natarajan(The University of Texas MD Anderson Cancer Center), Liangwen Xiong(The University of Texas MD Anderson Cancer Center), Baoxiang Guan(The University of Texas MD Anderson Cancer Center), Shalini S. Yadav(The University of Texas MD Anderson Cancer Center), Abdel Saci(Bristol-Myers Squibb (Sweden)), James P. Allison(The University of Texas MD Anderson Cancer Center), Matthew D. Galsky(Tisch Hospital), Padmanee Sharma(The University of Texas MD Anderson Cancer Center)
Cited by 128
Abstract
mutation as a combination biomarker in predicting response to ICT in CheckMate275 and IMvigor210. Combination of the two biomarkers in baseline tumor tissues suggested improved OS compared to either single biomarker. Cumulatively, this study revealed that the combination of CXCL13 plus ARID1A may improve prediction capability for patients receiving ICT.
Related Papers
No related papers found
Powered by citation graph analysis